The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis

Table 2

The results of direct analysis estimates of efficacy (hazard ratio).

Treatment	Study	ALT normalization			HBV DNA undetectable			HBeAg loss			HBeAg seroconversion
		HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
NA vs. NA add-on PEG IFN	Chi H et al. [8]; Brouwer WP et al. [6]	0.89	0.71-1.12	0.31	0.94	0.76-1.15	0.53	0.62	0.35-1.10	0.10	0.52	0.25-1.06	0.07
PEG IFN vs. PEG IFN add-on NA	Sun J et al. [9]; Xie Q et al. [10]	0.83	0.64-1.07	0.16	0.82	0.61-1.11	0.21	0.76	0.54-1.09	0.13	0.83	0.55-1.25	0.37
PEG IFN vs. NA	Xie Q et al. [10]	1.03	0.67-1.59	0.88	1.07	0.73-1.55	0.74	0.78	0.48-1.29	0.34	0.96	0.49-1.86	0.89
PEG IFN add-on NA vs. NA	Xie Q et al. [10]; Chan HL et al. [13]	1.14	0.89-1.47	0.30	0.74	0.53-1.03	0.08	1.21	0.85-1.73	0.29	1.31	0.86-1.99	0.21
PEG IFN vs. PEG IFN combined NA	Liu YH et al. [11]	0.89	0.48-1.64	0.70	0.52	0.27-1.00	0.04	NA	NA	NA	0.77	0.34-1.70	0.51
NA vs. NA switch PEG IFN	Ning Q et al. [7]	1.39	106-1.84	0.02	1.18	0.93-1.51	0.18	0.91	0.50-1.64	0.75	0.46	0.19-1.16	0.10
NA vs. PEG IFN combined NA	Lau GK et al. [12]	1.20	1.00-1.45	0.05	0.70	0.58-0.85	<0.01	0.84	0.62-1.14	0.27	0.88	0.64-1.22	0.45
NA vs. PEG IFN combined PLA	Lau GK et al. [12]	1.37	1.12-1.67	<0.01	1.42	1.09-1.85	0.01	1.34	0.95-1.90	0.09	0.80	0.58-1.10	0.17
PEG IFN combined NA vs. PEG IFN combined PLA	Lau GK et al. [12]; Janssen H et al. [14]	1.20	1.00-1.43	0.05	2.15	1.73-2.69	<0.01	NA	NA	NA	1.12	0.72-1.75	0.82

Note: NA, nucleoside/nucleotide analogs; PEG IFN, PEG IFNylated interferon; PLA, placebo; HR, hazard ratio.